Treats infections caused by susceptible isolates of the designated microorganisms in the…. ANDA 217723, held by Alembic. Ciprofloxacin; Dexamethasone.
As of Nov 16, 2026, ANDA 217723 (Ciprofloxacin And Dexamethasone), held by Alembic, was first approved by FDA on Oct 15, 2026, with 0 approved supplements and 0 published complete response letters.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 15, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ciprofloxacin And Dexamethasone0.3%;0.1% · suspension/drops;otic | Ciprofloxacin; Dexamethasone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters